News – Page 833 – Endpoints News

What's the hard cost of a pivotal drug trial? A lot less than you might expect

5 years ago

Roche’s anti-TIGIT drug shows zero response as monotherapy — but data back effect for lung cancer subset

5 years ago

Merck advances along a broad PhIII front, aimed at carving up Pfizer’s top-selling vaccine franchise. Could an ...

5 years ago

Sarepta expands gene therapy toolkit, bets $72.5M to hitch a ride on Codiak's exosome tech

5 years ago

FDA rejects Nabriva a second time; Nabriva pins it on travel restrictions

5 years ago

What’s this? A rival bidder heads back to the table with a better offer for Tetraphase. Antibiotics show faint ...

5 years ago

Trans-Atlantic VC banks $126M to scout startup ideas out of 'underventured' areas in the UK

5 years ago

Cell and gene therapy 2.0 dominates latest round of biotech IPOs in scramble for a $300M-plus Nasdaq windfall

5 years ago

Covid-19 roundup: In fifth open letter, Daniel O’Day touts inhalant remdesivir, promises 2M doses by year's end; ...

5 years ago

Surrozen reloads with $50M for final dash to the clinic, shines some light on lead Wnt-modulating candidates

5 years ago

Ultragenyx’s ultra-expensive ultra-rare disease drug earns second nod; Another round of promising NASH data

5 years ago

Prominent Harvard professor in the hunt for $100M to back his anti-aging play

5 years ago

Boehringer Ingelheim nabs new US president and CEO; AstraZeneca vet hops aboard Novavax as CMO

5 years ago

AbbVie sweeps out experimental gastro drugs in a post-merger pipeline cleanup. And they can likely be yours for the ...

5 years ago

The biotech IPOs keep coming at chart-topping levels — with no slowdown in sight

5 years ago

Covid-19 roundup: One Chinese biotech enters clinic, another eyes fall completion, a third shoots for 2021 — while ...

5 years ago

'A turning point for the field': 4 years after Seres failure, Finch posts positive microbiome data

5 years ago

Epizyme hits the ground running with second — and crucial — OK for Tazverik, in follicular lymphoma

5 years ago

Hours after blockbuster patent win, Mylan asks the FDA to speed up an OK to market a generic to Biogen’s Tecfidera

5 years ago

One of Roche’s spotlight PhIII cancer drug hopefuls stumbles in a key trial, with hit-and-miss results

5 years ago

AbbVie’s Rinvoq passes PhIII AD test; Dicerna races Alnylam; New Sarepta gene & cell collab

5 years ago

In a fresh blow, Biogen loses a big court fight with Mylan over its blockbuster Tecfidera patent

5 years ago

Nan Fung Life Sciences antes up $32M to fuel a neuro play as the Hong Kong conglomerate burns through $1.5B mandate

5 years ago

AbbVie-Allergan complete, but critics continue to raise anti-competitive concerns

5 years ago

First page Previous page 830 831 832833834 835 836 Next page Last page